SLNO INVESTOR ALERT: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action

San Diego, California--(Newsfile Corp. - April 17, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the "Class Period"), have until Tuesday, May 5, 2026 to seek appointment as lead plaintiff of the Soleno class action lawsuit. Captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979 (N.D. Cal.), the Soleno class action lawsuit charges Soleno and certain of Soleno's top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Soleno class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-soleno-therapeutics-inc-class-action-law ...

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/449-4900 or via e-mail at [e-mail].

CASE ALLEGATIONS: Soleno is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases. At the time of the Soleno class action lawsuit's filing, Soleno's only commercial product is diazoxide choline extended-release tablets ("DCCR") for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome ("PWS").

The Soleno class action lawsuit alleges defendants throughout the Class Period failed to disclose that: (i) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.